Jennifer Dwyer, MD
Payments from drug & device makers
What this record shows
20 manufacturers reported payments, led by Boston Scientific at 47.1% of the total. Reporting peaked in 2019 at $1,344 and has fallen 76.8% since, to $312 in 2025. That places this record below the midpoint for urology clinicians in NE, where the typical reported total is $2,774.
Across 42 payments — averaging $68.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$1K
- Axonics, Inc.$450
- Myovant Sciences Inc.$385
- KARL Storz Endoscopy-america$147
- Agiliti Surgical, Inc.$122
- Verity Pharmaceuticals Inc.$73
- plus $340 from 14 others
Across 1 payment — averaging $18,500 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Urogen Pharma, Inc.$19K
What the payments were for
- Travel & lodging$1,23343%
- Food & beverage$1,63757%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 7 | $1,352 |
| Axonics, Inc. | 4 | $450 |
| Myovant Sciences Inc. | 4 | $385 |
| KARL Storz Endoscopy-america | 3 | $147 |
| Agiliti Surgical, Inc. | 1 | $122 |
| Verity Pharmaceuticals Inc. | 4 | $73 |
| AbbVie(2 entities) | 4 | $57 |
| Dendreon Pharmaceuticals LLC | 2 | $57 |
| Teleflex LLC | 2 | $37 |
| Calyxo, Inc. | 1 | $25 |
| Procept Biorobotics Corporation | 1 | $22 |
| Sumitomo Pharma America, Inc. | 1 | $18 |
| Johnson & Johnson | 1 | $18 |
| Valencia Technologies Corporation | 1 | $17 |
| Olympus America Inc. | 1 | $16 |
| Endo Pharmaceuticals Inc. | 1 | $15 |
| Merck | 1 | $15 |
| Caldera Medical, Inc | 1 | $15 |
| Tolmar, Inc. | 1 | $14 |
| Coloplast | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AMS$1,206
- ORGOVYX$359
- Axonics$305
- Axonics r-SNM System$136
- Sonablate HIFU$122
- Koelis Trinity MRI/US Fusion$122
- CMOS VIDECYSTURETHROSCOPE US$109
How this compares
$2,870 in reported general payments places this provider in the 50th percentile of 79 urology providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 114 | $73,985 |
| GemtesaVibegron | 78 | $49,553 |
| Estradiol | 93 | $7,992 |
| Trospium Chloride ErTrospium Chloride | 31 | $4,945 |
| Mirabegron ErMirabegron | 11 | $3,947 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 90 | $3,416 |
| Methenamine Hippurate | 48 | $2,138 |
| Cefdinir | 47 | $1,990 |
| Potassium Citrate ErPotassium Citrate | 12 | $1,784 |
| Trospium Chloride | 27 | $1,643 |
| Tamsulosin Hcl | 126 | $1,586 |
| Oxybutynin Chloride ErOxybutynin Chloride | 56 | $949 |
| Solifenacin Succinate | 28 | $663 |
| Finasteride | 67 | $578 |
| Bethanechol Chloride | 18 | $559 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $18 | $49,55378 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 79 urology providers in Nebraska.
Other urology in Omaha
- John BishayOmaha$138K
- Rebecca McCreryOmaha$71K
- Judson DaviesOmaha$67K
- Stefanie BolteOmaha$59K
- Michael FeloneyOmaha$29K
- Andrew TrainerOmaha$12K
- Stephen LeslieOmaha$12K
- Jon MortonOmaha$11K
- Brett HillOmaha$11K
- John HorganOmaha$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.